Evommune Announces Top Line Data from Phase 2 Trial of EVO756 in Chronic Inducible Urticaria.
Read More
About Us
Overview
Leadership
Collaborating
Contact
Our Science
Approach
Disease Focus
Publications & Posters
Our Pipeline
Development Pipeline
MRGPRX2 Antagonist
IL-18 Fusion Protein
Clinical Trials
Join Us
Our Culture
Job Openings
Newsroom
Press Releases
Select Page
back to management
RTW
14 of 17
14 of 17
